非标签NOACs与AF相关中风中的抗血小板药物,GFR<15mL/Min/1.73m2:一个多中心结局研究
Jong-Hee Sohn1,2, Minwoo Lee3, Chulho Kim1,2
1Department of Neurology, Chuncheon Sacred Heart Hospital, Hallym University College of Medicine, Chuncheon 24252, Republic of Korea.
Biomedicines
|December 30, 2025
概括
对于心房相关的中风和功能非常低的患者,非维生素K对抗剂口服抗凝剂 (NOACs) 可能减少中风复发,但与抗血小板治疗相比,增加出血和死亡风险.
科学领域:
- 神经学 神经学
- 腎臟病學 (nephrology) 是一種醫學專業.
- 药理学 药理学是指药理学的学科.
背景情况:
- 评估非维生素K对手口服抗凝剂 (NOACs) 与抗血小板治疗 (APT) 对与心房相关的急性缺血性中风 (AIS) 在估计膜过率 (GFR) <15 mL/min/1.73 m2的患者.
- 评估严重功能障碍的脆弱患者群体的疗效和安全性.
研究的目的:
- 为了比较NOAC与APT在患有AF相关的AIS和超低GFR的患者中的有效性和安全性.
- 为了确定一年内对中风复发,重大出血和全因死亡率的影响.
主要方法:
- 利用一个多中心的潜在中风注册表来识别符合条件的患者.
- 仅用APT出院的患者与仅用低剂量NOACs出院的患者之间的结果比较.
- 使用Cox比例危险回归来计算调整的危险比率 (aHR) 和95%置信区间 (CI).
主要成果:
- 176名患者接受了NOAC,135人接受了APT.
- 使用NOAC与显著降低缺血性中风复发率有关 (aHR为0.54,95%CI为0.29-0.99).
- 使用NOAC与较高的严重出血风险 (aHR 3.25,95% CI 1.84-5.73) 和所有原因死亡率 (aHR 2.65,95% CI 1.60-4.38) 相关.
结论:
- 在AF相关中风患者中非标签的NOAC使用,GFR超低可能会改善中风预防,但会增加出血和死亡风险.
- 诸如败血症之类的非血管事件是主要的死亡原因.
- 个性化治疗策略和密切监测对于这个高危人群至关重要.
相关概念视频
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
1.0K
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.0K
Atherosclerosis III: Management
291
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
291
Peripheral Artery Disease III: Interprofessional Care
217
Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
217
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
2.7K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
2.7K
Acute Coronary Syndrome III: Diagnostic Studies
194
Diagnosing acute coronary syndrome or ACS begins with a thorough patient history. Notable symptoms include central, crushing chest pain radiating to the left arm, neck, jaw, or back, along with shortness of breath, sweating (diaphoresis), nausea, vomiting, dizziness, and palpitations.It is crucial to note any history of cardiac illnesses and assess risk factors, including age, gender, smoking, hypertension, diabetes, hyperlipidemia, and a sedentary lifestyle.During physical examination, vital...
194
Acute Coronary Syndrome I: Introduction
700
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
700


